GleamWall
中文EN

MEDP Medpace Holdings, Inc.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1668397 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY20.4%
TTM net income YoY19.6%
TTM EPS YoY25.9%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR23.8%

Margins

Gross margin—
Operating margin21.4%
Net margin18.2%
FCF margin23.5%
EBITDA margin22.3%

Returns

ROE117.9%
ROA25.5%
ROIC (approx.)—
Asset turnover1.40x

Leverage & solvency

Liabilities / assets74.6%
Debt / equity0.00x
Current ratio0.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.40x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$716.00M$707.33M$706.60M$708.45M$659.90M$603.31M$558.57M$536.59M
SG&A expense$51.77M$48.10M$47.92M$44.92M$48.08M$46.66M$57.90M$45.43M
Operating income$165.54M$146.82M$141.50M$153.27M$141.81M$126.33M$113.52M$125.38M
Pretax income$170.91M$151.66M$147.59M$156.83M$142.84M$124.54M$118.17M$133.88M
Income tax$33.45M$30.30M$23.72M$21.70M$31.70M$34.28M$3.58M$16.86M
Net income$137.46M$121.36M$123.87M$135.13M$111.14M$90.26M$114.59M$117.02M
EBITDA$171.97M$153.38M$148.25M$160.16M$148.62M$133.11M$120.22M$132.52M
EPS (basic)4.924.314.35—3.953.163.77—
EPS (diluted)4.844.254.28—3.863.103.67—
Weighted avg. shares (diluted)28.37M28.55M28.96M—28.82M29.14M31.20M—
Balance sheet
Cash & equivalents$705.32M$502.69M$652.68M$497.05M$285.35M$46.33M$441.44M$669.44M
Receivables$447.64M$441.80M$394.58M$402.08M$373.03M$377.92M$298.22M$296.44M
Current assets$1.25B$1.05B$1.14B$989.62M$737.28M$520.80M$821.44M$1.03B
PP&E, net$175.00M$157.11M$136.55M$131.06M$133.18M$135.48M$128.33M$123.61M
Goodwill$662.40M$662.40M$662.40M$662.40M$662.40M$662.40M$662.40M$662.40M
Intangibles$32.95M$33.11M$33.27M$33.42M$33.66M$33.89M$34.13M$34.37M
Total assets$2.30B$2.06B$2.13B$1.98B$1.75B$1.57B$1.90B$2.10B
Current liabilities$1.50B$1.44B$1.35B$1.34B$1.28B$1.22B$1.12B$1.10B
Total liabilities$1.72B$1.62B$1.53B$1.52B$1.46B$1.40B$1.30B$1.28B
Shareholders' equity$584.94M$433.86M$598.31M$459.07M$293.64M$172.35M$593.61M$825.54M
Shares outstanding27.97M27.91M28.56M28.37M28.17M28.09M29.84M30.63M
Cash flow statement
Operating cash flow$216.60M$162.01M$151.79M$192.65M$246.21M$148.53M$125.84M$190.67M
Capital expenditure$20.16M$23.91M$6.81M$4.54M$10.71M$6.11M$9.99M$7.64M
Free cash flow$196.44M$138.10M$144.97M$188.12M$235.50M$142.41M$115.84M$183.02M
Investing cash flow-$20.14M-$23.89M-$6.75M-$4.47M-$10.66M-$6.02M-$9.99M-$7.56M
Financing cash flow$6.50M-$288.34M$12.67M$22.73M$3.41M-$540.56M-$345.97M-$168.61M
Depreciation & amortization$6.42M$6.55M$6.75M$6.89M$6.81M$6.78M$6.69M$7.14M
Stock-based compensation$7.60M$4.35M$4.92M$5.62M$6.32M$5.95M$16.89M$5.89M
Share buybacks$0$294.76M$0$0$4.57M$540.91M$371.90M$169.87M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.